How off-patent strategies benefit patient care

Graeme Duncan, CEO at ADVANZ PHARMA, discusses how targeted strategic investment within the off-patent sector can add value and enhance choice for patients and healthcare professionals alike, while helping to drive and maintain innovation within the pharmaceutical industry.

close up of a person stacking wooden blocks with various health and medicine related symbols

THE OFF-PATENT sector has a long track record of careful strategic decision‑making to deliver increased patient choice and greater access to affordable medicines. A large part of this strategy centres on the organic growth of a company’s pipeline assets, while the remainder tends to revolve around mergers and acquisitions (M&A) of products and companies. At ADVANZ PHARMA, M&A have played an integral part in how we can broaden our offering, strengthen our capabilities and ultimately provide greater patient and clinician choice when it comes to off-patent, complex medicines. Here, I share how our strategic approach in the off-patent sector has helped to drive innovation across a wide range of therapy areas.

    To read this article in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Catalent

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend